The New Biotech Model
In the meantime, one biotech model gaining traction is the single asset, infrastructure-lite, development model, which deploys modest amounts of capital to develop a single compound to an early clinical data package which can be partnered with pharma. The asset resides within an LLC, and following the license transaction, the LLC is wound down and … Read more
A cauldron of poisonous forecasts…
What to make of today’s data, reports, and financial news? Seems market sentiment has turned on a dime from bullish to down-right grim. Prospects of “double-dip” have increased, organic growth remains invisible, and the “new normal” has consumers changing their spending habits even in the cases of those who don’t need to. Gold prices, a … Read more
El-Erian hangs onto Uncertainty
“The minute someone puts out a green light, and earnings constituted a green light, you’ll see people rushing back into risk markets,” El-Erian said. “The indicators that we look at suggest that the economy continues to lose momentum. The key is going to be ultimately is the economy creating enough jobs to make people comfortable, to allow companies to invest?”
Markets Pricing In Global ‘Paradigm Change’: El-Erian – CNBC
{{desc}} via Markets Pricing In Global ‘Paradigm Change’: El-Erian – CNBC.
